Treating BRAF V600-mutated melanomas with a BRAF and MEK inhibitor significantly increases survival outcome. Nevertheless, resistance mechanisms, as well as negative predictive biomarkers (elevated lactate dehydrogenase levels, high number of metastatic organ disease sites, brain...
Are we approaching a true cure in BRAF-mutated melanoma?
